At Qlarisour Lead Program Is Qls 111A Novel Topical Ocular Therapy That Lowers Intraocular Pressure With A Unique Mechanism Of Actionqls 111 Is Distinct From Currently Available Therapies By Selectively Targeting Episcleral Venous Pressureevpand Improving Outflow Distal To The Trabecular Meshworkthis Novel Mechanism May Enable The Improved Treatment Of Diseases Where Evp Has Limited Therapy Or Has Itself Been Pathologicsuch As Normal Tension Glaucomaprimary Open Angle Glaucomaglaucoma Associated With Sturge Weber Syndromeand Also In Combination With Minimally Invasive Glaucoma Surgerymigsdevices
